UNCY
Unicycive Therapeutics, Inc.
Price Chart
Latest Quote
$3.61
+0.03 (+0.84%)
Current Price
| Previous Close | $3.58 |
| Open | $3.60 |
| Day High | $3.69 |
| Day Low | $3.48 |
| Volume | 1,340,066 |
Stock Information
| Shares Outstanding | 27.39M |
| Total Debt | $671K |
| Cash Equivalents | $61.42M |
| Net Income | $-35.22M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $98.89M |
| EPS (TTM) | $-1.72 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $39.80M |
| Income | $-35.22M |
| Book/sh | $1.91 |
| Cash/sh | $2.24 |
| Employees | 21 |
Financial Ratios
| Quick Ratio | 3.28 |
| Current Ratio | 3.81 |
| Debt/Eq | 1.26 |
Returns & Margins
| ROA | -40.59% |
| ROE | -101.07% |
Ownership
| Insider Ownership | 2.26% |
| Institutional Ownership | 42.54% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 2.49 |
| P/B | 1.89 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $28.40 |
Technical Indicators
| SMA20 | $3.94 |
| SMA50 | $4.65 |
| SMA200 | $6.14 |
| RSI | 34.76 |
| ATR | 0.2514 |
| Shares Float | 27.21M |
| Short Float | 17.83% |
| Short Ratio | 5.57 |
| Volatility | 1.82 |
| Rel Volume | 1.24 |
Performance History
| Week | -5.00% |
| Month | -22.20% |
| Quarter | -23.84% |
| 6 Months | -49.65% |
| YTD | -37.76% |
| Year | -29.63% |
| 3 Years | -58.51% |
| 5 Years | -85.84% |
| 10 Years | -92.78% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $3.61 | 1,341,300 |
| 2026-10-26 | $3.58 | 1,326,800 |
| 2026-10-23 | $3.89 | 1,212,400 |
| 2026-10-22 | $3.94 | 742,800 |
| 2026-10-21 | $3.87 | 1,437,900 |
| 2026-10-20 | $3.80 | 1,207,900 |
| 2026-10-19 | $3.51 | 1,126,600 |
| 2026-10-16 | $3.36 | 1,102,300 |
| 2026-10-15 | $3.59 | 893,000 |
| 2026-10-14 | $3.70 | 1,208,800 |
| 2026-10-13 | $3.73 | 1,836,600 |
| 2026-10-12 | $4.05 | 912,800 |
| 2026-10-09 | $4.11 | 551,400 |
| 2026-10-08 | $4.07 | 1,176,100 |
| 2026-10-07 | $4.18 | 590,700 |
| 2026-10-06 | $4.23 | 785,400 |
| 2026-10-05 | $4.19 | 681,400 |
| 2026-10-02 | $4.22 | 1,510,100 |
| 2026-10-01 | $4.55 | 1,068,800 |
| 2026-09-30 | $4.70 | 862,700 |
| 2026-09-29 | $4.55 | 2,306,600 |
| 2026-09-28 | $4.64 | 601,500 |
About Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on UNCY.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $675,000 | $951,000 |
| Operating Revenue | $0 | $0 | $675,000 | $951,000 |
| Expenses | ||||
| Interest Expense | $71,000 | $71,000 | $82,000 | $6,000 |
| Total Expenses | $29,517,000 | $32,117,000 | $21,449,000 | $19,003,000 |
| Other Income Expense | $2,021,000 | $-5,802,000 | $-10,303,000 | - |
| Net Non Operating Interest Income Expense | $941,000 | $1,190,000 | $533,000 | $-6,000 |
| Interest Expense Non Operating | $71,000 | $71,000 | $82,000 | $6,000 |
| Operating Expense | $29,517,000 | $32,117,000 | $21,449,000 | $19,003,000 |
| General And Administrative Expense | $20,396,000 | $12,103,000 | $8,547,000 | $6,567,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-26,555,000 | $-36,729,000 | $-30,544,000 | $-18,058,000 |
| Net Interest Income | $941,000 | $1,190,000 | $533,000 | $-6,000 |
| Interest Income | $1,012,000 | $1,261,000 | $615,000 | $0 |
| Normalized Income | $-28,576,000 | $-30,927,000 | $-20,241,000 | $-18,058,000 |
| Net Income From Continuing And Discontinued Operation | $-26,555,000 | $-36,729,000 | $-30,544,000 | $-18,058,000 |
| Total Operating Income As Reported | $-29,517,000 | $-32,117,000 | $-20,774,000 | $-18,052,000 |
| Net Income Common Stockholders | $-26,555,000 | $-37,824,000 | $-31,411,000 | $-18,058,000 |
| Net Income | $-26,555,000 | $-36,729,000 | $-30,544,000 | $-18,058,000 |
| Net Income Including Noncontrolling Interests | $-26,555,000 | $-36,729,000 | $-30,544,000 | $-18,058,000 |
| Net Income Continuous Operations | $-26,555,000 | $-36,729,000 | $-30,544,000 | $-18,058,000 |
| Pretax Income | $-26,555,000 | $-36,729,000 | $-30,544,000 | $-18,058,000 |
| Interest Income Non Operating | $1,012,000 | $1,261,000 | $615,000 | $0 |
| Operating Income | $-29,517,000 | $-32,117,000 | $-20,774,000 | $-18,052,000 |
| Special Income Charges | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-1.67 | $-5.65 | $-12.80 | $-12.00 |
| Basic EPS | $-1.67 | $-5.65 | $-12.80 | $-12.00 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-27,933,000 | $-30,428,000 | $-19,875,000 | $-17,891,000 |
| Total Unusual Items | $2,021,000 | $-5,802,000 | $-10,303,000 | $0 |
| Total Unusual Items Excluding Goodwill | $2,021,000 | $-5,802,000 | $-10,303,000 | $0 |
| Reconciled Depreciation | $572,000 | $428,000 | $284,000 | $161,000 |
| EBITDA (Bullshit earnings) | $-25,912,000 | $-36,230,000 | $-30,178,000 | $-17,891,000 |
| EBIT | $-26,484,000 | $-36,658,000 | $-30,462,000 | $-18,052,000 |
| Diluted Average Shares | $15,886,876 | $6,698,513 | $2,453,930 | $1,505,704 |
| Basic Average Shares | $15,886,876 | $6,698,513 | $2,453,930 | $1,505,704 |
| Diluted NI Availto Com Stockholders | $-26,555,000 | $-37,824,000 | $-31,411,000 | $-18,058,000 |
| Gain On Sale Of Security | $2,021,000 | $-5,802,000 | $-10,303,000 | - |
| Research And Development | $9,121,000 | $20,014,000 | $12,902,000 | $12,436,000 |
| Selling General And Administration | $20,396,000 | $12,103,000 | $8,547,000 | $6,567,000 |
| Other Gand A | $20,396,000 | $12,103,000 | $8,547,000 | $6,567,000 |
| Preferred Stock Dividends | - | $1,095,000 | $867,000 | - |
| Other Special Charges | - | - | - | - |
Fetched: 2026-10-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $30,197,000 | $7,431,000 | $-3,809,000 | $-466,000 |
| Total Assets | $49,135,000 | $31,668,000 | $14,191,000 | $2,818,000 |
| Total Non Current Assets | $174,000 | $720,000 | $792,000 | $174,000 |
| Current Assets | $48,961,000 | $30,948,000 | $13,399,000 | $2,644,000 |
| Other Current Assets | $1,171,000 | $939,000 | $325,000 | $159,000 |
| Prepaid Assets | $6,521,000 | $3,867,000 | $3,373,000 | $2,030,000 |
| Cash Cash Equivalents And Short Term Investments | $41,269,000 | $26,142,000 | $9,701,000 | $455,000 |
| Cash And Cash Equivalents | $29,198,000 | $26,142,000 | $9,701,000 | $455,000 |
| Cash Financial | $29,198,000 | $26,142,000 | $9,701,000 | $455,000 |
| Current Deferred Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $199,000 | $773,000 | $811,000 | $201,000 |
| Long Term Debt And Capital Lease Obligation | $0 | $117,000 | $466,000 | $0 |
| Current Debt And Capital Lease Obligation | $199,000 | $656,000 | $345,000 | $201,000 |
| Current Debt | $82,000 | $92,000 | $18,000 | $46,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $18,938,000 | $24,237,000 | $18,000,000 | $3,284,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $117,000 | $466,000 | $0 |
| Current Liabilities | $18,938,000 | $24,120,000 | $17,534,000 | $3,284,000 |
| Other Current Liabilities | $16,915,000 | $18,936,000 | $13,134,000 | - |
| Payables And Accrued Expenses | $1,824,000 | $4,528,000 | $4,055,000 | $3,083,000 |
| Payables | $301,000 | $966,000 | $821,000 | $846,000 |
| Accounts Payable | $301,000 | $966,000 | $821,000 | $846,000 |
| Equity | ||||
| Common Stock Equity | $30,197,000 | $7,431,000 | $-3,809,000 | $-466,000 |
| Total Equity Gross Minority Interest | $30,197,000 | $7,431,000 | $-3,809,000 | $-466,000 |
| Stockholders Equity | $30,197,000 | $7,431,000 | $-3,809,000 | $-466,000 |
| Gains Losses Not Affecting Retained Earnings | $-1,000 | $0 | - | - |
| Other Equity Adjustments | $-1,000 | - | - | - |
| Retained Earnings | $-127,825,000 | $-101,270,000 | $-64,541,000 | $-33,997,000 |
| Other | ||||
| Ordinary Shares Number | $22,114,245 | $11,384,236 | $3,475,604 | $1,523,165 |
| Share Issued | $22,114,245 | $11,384,236 | $3,475,604 | $1,523,165 |
| Tangible Book Value | $30,197,000 | $7,431,000 | $-3,809,000 | $-466,000 |
| Invested Capital | $30,279,000 | $7,523,000 | $-3,791,000 | $-420,000 |
| Working Capital | $30,023,000 | $6,828,000 | $-4,135,000 | $-640,000 |
| Capital Lease Obligations | $117,000 | $681,000 | $793,000 | $155,000 |
| Total Capitalization | $30,197,000 | $7,431,000 | $-3,809,000 | $-466,000 |
| Additional Paid In Capital | $158,001,000 | $108,690,000 | $60,697,000 | $33,516,000 |
| Capital Stock | $22,000 | $11,000 | $35,000 | $15,000 |
| Common Stock | $22,000 | $11,000 | $35,000 | $15,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $0 | $117,000 | $466,000 | $0 |
| Current Capital Lease Obligation | $117,000 | $564,000 | $327,000 | $155,000 |
| Line Of Credit | $82,000 | $92,000 | $18,000 | $46,000 |
| Current Accrued Expenses | $1,523,000 | $3,562,000 | $3,234,000 | $2,237,000 |
| Net PPE | $174,000 | $720,000 | $792,000 | $174,000 |
| Accumulated Depreciation | $-72,000 | $-39,000 | $-16,000 | $-7,000 |
| Gross PPE | $246,000 | $759,000 | $808,000 | $181,000 |
| Leases | $65,000 | $49,000 | $21,000 | $15,000 |
| Other Properties | $26,000 | $26,000 | - | - |
| Machinery Furniture Equipment | $47,000 | $39,000 | $21,000 | $14,000 |
| Buildings And Improvements | $108,000 | $645,000 | $766,000 | $152,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $12,071,000 | $0 | - | - |
| Construction In Progress | - | $10,000 | $0 | - |
| Dueto Related Parties Current | - | - | - | - |
Fetched: 2026-10-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-31,341,000 | $-28,647,000 | $-18,295,000 | $-15,653,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-31,317,000 | $-28,575,000 | $-18,283,000 | $-15,651,000 |
| Cash Flow From Continuing Operating Activities | $-31,317,000 | $-28,576,000 | $-18,283,000 | $-15,651,000 |
| Operating Gains Losses | $-2,021,000 | $5,802,000 | $10,303,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-24,000 | $-72,000 | $-12,000 | $-2,000 |
| Investing Cash Flow | $-12,095,000 | $-72,000 | $-12,000 | $-2,000 |
| Cash Flow From Continuing Investing Activities | $-12,095,000 | $-72,000 | $-12,000 | $-2,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $46,582,000 | $50,683,000 | $30,190,000 | $11,000 |
| Financing Cash Flow | $46,468,000 | $45,088,000 | $27,541,000 | $-471,000 |
| Cash Flow From Continuing Financing Activities | $46,468,000 | $45,088,000 | $27,541,000 | $-471,000 |
| Net Other Financing Charges | $-1,610,000 | $-4,500,000 | $-2,649,000 | $-482,000 |
| Cash Dividends Paid | $0 | $-1,095,000 | $0 | - |
| Net Preferred Stock Issuance | $0 | $50,000,000 | $30,190,000 | $0 |
| Preferred Stock Issuance | $0 | $50,000,000 | $30,190,000 | $0 |
| Net Common Stock Issuance | $46,582,000 | $683,000 | $0 | $11,000 |
| Common Stock Issuance | $46,582,000 | $683,000 | $0 | $11,000 |
| Other | ||||
| Interest Paid Supplemental Data | $0 | $12,000 | $24,000 | $6,000 |
| End Cash Position | $29,198,000 | $26,142,000 | $9,701,000 | $455,000 |
| Beginning Cash Position | $26,142,000 | $9,701,000 | $455,000 | $16,579,000 |
| Changes In Cash | $3,056,000 | $16,441,000 | $9,246,000 | $-16,124,000 |
| Proceeds From Stock Option Exercised | $1,496,000 | $0 | - | $0 |
| Net Investment Purchase And Sale | $-12,071,000 | $0 | - | - |
| Purchase Of Investment | $-12,071,000 | $0 | - | - |
| Net PPE Purchase And Sale | $-24,000 | $-72,000 | $-12,000 | $-2,000 |
| Purchase Of PPE | $-24,000 | $-72,000 | $-12,000 | $-2,000 |
| Change In Working Capital | $-5,954,000 | $-427,000 | $-93,000 | $1,178,000 |
| Change In Other Current Liabilities | $-565,000 | $-397,000 | $-252,000 | $-151,000 |
| Change In Payables And Accrued Expense | $-2,505,000 | $790,000 | $1,276,000 | $1,267,000 |
| Change In Payable | $-2,505,000 | $790,000 | $1,276,000 | $1,267,000 |
| Change In Account Payable | $-2,505,000 | $790,000 | $1,276,000 | $1,267,000 |
| Change In Prepaid Assets | $-2,884,000 | $-820,000 | $-1,117,000 | $62,000 |
| Stock Based Compensation | $2,641,000 | $2,350,000 | $1,767,000 | $1,047,000 |
| Depreciation Amortization Depletion | $572,000 | $428,000 | $284,000 | $161,000 |
| Depreciation And Amortization | $572,000 | $428,000 | $284,000 | $161,000 |
| Depreciation | $572,000 | $428,000 | $284,000 | $161,000 |
| Gain Loss On Investment Securities | $-2,021,000 | $5,802,000 | $10,303,000 | - |
| Net Income From Continuing Operations | $-26,555,000 | $-36,729,000 | $-30,544,000 | $-18,058,000 |
| Income Tax Paid Supplemental Data | - | $0 | $0 | $0 |
| Other Non Cash Items | - | $1,000 | - | $21,000 |
| Repayment Of Debt | - | - | - | $0 |
| Issuance Of Debt | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
| Pension And Employee Benefit Expense | - | - | - | $0 |
Fetched: 2026-10-20